Introduction: Diabetic papillopathy is a rare ocular complication of diabetes. Its pathophysiology is not well known. It is a unilateral or bilateral optic disc edema with variable degrees of visual loss.
Observation: A 66-year-old woman, with a twelve years old type 2 diabetes mellitus, suddenly presented a unilateral decreased vision. Her ocular examination was normal eight months earlier. Ocular examination, radiological investigations and laboratory analysis were conclusive of diabetic papillopathy. Medical history revealed a recent rapid improvement of blood glucose control after intensification of insulin therapy. A visual acuity improvement with spontaneous regression of papillary edema was observed.
Conclusion: There is a risk of diabetic papillopathy associated with the rapid control of blood glucose levels after intensification of insulin therapy, even in diabetic patients without known retinopathy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.revmed.2018.08.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of 3-Nitrooxypropanol Combined with Different Feed Additives on Growth Performance, Carcass Traits, Enteric Methane Emissions, and Physiological Responses in Feedlot Beef Cattle Fed a High-Concentrate Finishing Diet.
Animals (Basel)
December 2024
Department of Animal Science, Faculty of Agricultural and Veterinary Sciences, São Paulo State University, Jaboticabal 14884-900, SP, Brazil.
The objective of this study was to evaluate the effect of 3-nitrooxypropanol (3-NOP) in combination with different feed additives on growth performance, carcass traits, meat quality, enteric methane (CH) emissions, nutrient intake and digestibility, and blood parameters in feedlot beef cattle. In experiment (Exp.) 1, one hundred sixty-eight Nellore bulls (initial bodyweight (BW) 410 ± 8 kg) were allocated to 24 pens in a completely randomized block design.
View Article and Find Full Text PDFExploring disparities: A comparative analysis of insulin-naïve, regular users, and inertia patients among type 2 diabetes mellitus outpatients in India.
J Family Med Prim Care
October 2024
Department of General Medicine, All India Institute of Medical Sciences Bhopal, Bhopal, Madhya Pradesh, India.
Introduction: Insulin utilization pattern varies greatly in type 2 diabetes mellitus (T2DM) patients. Clinical inertia in treatment intensification hinders glycemic control in T2DM management. This study investigated insulin prescription trends and various predictors among insulin naive, user, and insulin inertia (II) patients in T2DM.
View Article and Find Full Text PDFThe Action of Colchicine in Patients with Metabolic Syndrome and Obesity: Perspectives and Challenges.
Metabolites
November 2024
Faculty of Medicine, Federal University of Bahia (UFBA), Salvador 40110-060, BA, Brazil.
Colchicine is an alkaloid traditionally used to treat inflammatory conditions such as gout and familial Mediterranean fever. Currently, there are proposals for the use of this drug in several other situations, such as cardiovascular and liver diseases and diabetes. In this study, the current literature on the potential of colchicine in the treatment of obesity and metabolic syndrome (MS) was evaluated.
View Article and Find Full Text PDFMetformin effectively alleviates the symptoms of Alzheimer in rats by lowering amyloid β deposition and enhancing the insulin signal.
Metab Brain Dis
November 2024
Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, 31527, Egypt.
Alzheimer's disease (AD) exhibits distinct biochemical and histopathological attributes, encompassing cellular, neuronal, and oxidative impairment. There is also an abnormal buildup, misfolding and clumping of amyloid β (Aβ). The present study aimed to explore the influence of the antihyperglycemic agent metformin on rats with AD-like symptoms, while also elucidating the intricate relationship between insulin resistance and AD.
View Article and Find Full Text PDFDe-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).
Diabetes Obes Metab
November 2024
Department of Endocrinology, Cleveland Clinic, Cleveland, Ohio, USA.
Aims: The study aims to examine the outcome of replacement of prandial insulin with once-weekly subcutaneous semaglutide in people with type 2 diabetes reasonably controlled on multiple daily insulin injections (MDI).
Materials And Methods: This single-centre, randomised, open-label trial enrolled a statistically predetermined sample of 60 adults with HbA1c ≤7.5% (58 mmol/mol) receiving MDI, with a total daily dose (TDD) ≤120 units/day.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!